TruSight Oncology Comprehensive (EU)

Generate a comprehensive genomic profile of the patient sample

• Detect DNA plus RNA variants and biomarker signatures, such as TMB and MSI, for all multiple solid tumor types
• Increase confidence in ensuring the best treatment decisions
• Consolidate multiple individual biomarkers into a single CGP test, saving sample, time, and costs

Enable targeted therapies and clinical trials

• Content includes key biomarkers associated with drug labels, European Society for Medical Oncology (ESMO) recommendations, and clinical trials for multiple solid tumor types

• Test results help inform therapy decisions according to clinical guidelines
• TruSight Oncology Comprehensive (EU) is also indicated as a companion diagnostic test to identify cancer patients with solid tumors who are positive for NTRK1, NTRK2, or NTRK3 gene fusions, for treatment with VITRAKVI® (larotrectinib) in accordance with the approved therapeutic labeling.
• Under development, an extensive pipeline of additional companion diagnostic claims with the goal of enabling identification of patients likely to respond to specific targeted therapies

Offer the test in your institution

• Rely on a distributed IVD sample-to-answer solution validated by Illumina that can be implemented by local labs
• Broaden potential patient access and reduce turnaround time
• Offer precision oncology in your institution, keep the data in your lab, and avoid losing samples to send-out services, reducing the likelihood of quantity not sufficient (QNS) issues and potentially enabling more informed cases